CPHI - Despite audit finding 'substantial doubt' about future China Pharma shares soar 43% (updated)

An audit opinion issued by an independent accounting firm says that current liabilities and accumulated deficits has raised "substantial doubt" about China Pharma's (CPHI) ability to continue.The company's full-year 2020 results, released Friday, showed GAP EPS of -$0.07 and total revenue of ~$10.9M.The company's bad debt expenses for 2020 was $115,186 compared to $3,153 in 2019.China Pharma shares, however, are up 37% to $1.14 in morning trading.

For further details see:

Despite audit finding 'substantial doubt' about future, China Pharma shares soar 43% (updated)